Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?

被引：8
作者：
Megna, Matteo [1 ]
Marasca, Claudio [1 ]
Ruggiero, Angelo [1 ]
Camela, Elisa [1 ]
Fabbrocini, Gabriella [1 ]
机构：
[1] Univ Naples Federico II, Dept Clin Med & Surg, Dermatol Sect, Naples, Italy
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2020年 / 59卷 / 08期
关键词：
D O I：
10.1111/ijd.14902
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E308 / E309
页数：2
相关论文
共 10 条
  • [1] Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature
    Andreadou, E.
    Kemanetzoglou, E.
    Brokalaki, Ch.
    Evangelopoulos, M. E.
    Kilidireas, C.
    Rombos, A.
    Stamboulis, E.
    [J]. CASE REPORTS IN NEUROLOGICAL MEDICINE, 2013, 2013
  • [2] Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient
    Assefa, Girum T.
    Kaneko, Sakae
    Oguro, Hiroaki
    Morita, Eishin
    [J]. JOURNAL OF DERMATOLOGY, 2019, 46 (03) : E112 - E113
  • [3] The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
    Brembilla, Nicolo Costantino
    Senra, Luisa
    Boehncke, Wolf-Henning
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [4] A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions
    Diebold, Martin
    Mueller, Simon
    Derfuss, Tobias
    Decard, Bernhard F.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 : 38 - 40
  • [5] A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic
    Edwards, LJ
    Constantinescu, CS
    [J]. MULTIPLE SCLEROSIS, 2004, 10 (05): : 575 - 581
  • [6] Multiple sclerosis association with psoriasis: a large US population, single centre, retrospective cross-sectional study
    Guido, N.
    Cices, A.
    Ibler, E.
    Huynh, T.
    Majewski, S.
    Sable, K.
    Rangel, S. M.
    West, D. P.
    Laumann, A. E.
    Nardone, B.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (09) : E404 - E406
  • [7] Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study
    Havrdova, Eva
    Belova, Anna
    Goloborodko, Alla
    Tisserant, Anne
    Wright, Andrew
    Wallstroem, Erik
    Garren, Hideki
    Maguire, Ralph Paul
    Johns, Donald R.
    [J]. JOURNAL OF NEUROLOGY, 2016, 263 (07) : 1287 - 1295
  • [8] IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
    Kolbinger, Frank
    Huppertz, Christine
    Mir, Anis
    Di Padova, Franco
    [J]. CURRENT DRUG TARGETS, 2016, 17 (16) : 1882 - 1893
  • [9] Psoriasis and comorbid diseases Epidemiology
    Takeshita, Junko
    Grewal, Sungat
    Langan, Sinead M.
    Mehta, Nehal N.
    Ogdie, Alexis
    Van Voorhees, Abby S.
    Gelfand, Joel M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) : 377 - 390
  • [10] Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report
    Venturini, M.
    Zanca, A.
    Venturuzzo, A.
    Filippini, M.
    Frassi, M.
    Tincani, A.
    Calzavara-Pinton, P. G.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (02) : E110 - E112
1